SANA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
-18506000
-128.3%
65.4M
+34.6%
48.6M
-20.6%
61.2M
+40.6%
43.5M
R&D
-29449000
-153.9%
54.6M
+47.1%
37.2M
+89.7%
19.6M
-41.1%
33.2M
SG&A
10.9M
+1.5%
10.8M
-6.0%
11.5M
-5.9%
12.2M
+18.5%
10.3M
Operating Income
18.5M
+128.3%
-65420000
-34.6%
-48614000
+20.6%
-61199000
-40.6%
-43515000
EBITDA
21.5M
+134.0%
-63186000
-36.7%
-46223000
+20.5%
-58146000
-44.2%
-40324000
Net Income
20.4M
+132.1%
-63635000
-34.8%
-47210000
+19.7%
-58825000
-39.6%
-42152000
EPS (Basic)
$0.07
+131.8%
$-0.22
-29.4%
$-0.17
+19.0%
$-0.21
-31.2%
$-0.16
EPS (Diluted)
$0.07
+131.8%
$-0.22
-29.4%
$-0.17
+19.0%
$-0.21
-31.2%
$-0.16
Shares (Diluted)
308.8M
+4.4%
295.7M
+6.8%
276.9M
+0.1%
276.5M
+6.1%
260.5M
Sana Biotechnology (SANA) — Financials